Specialist pharmaceutical company Elite Pharmaceuticals Inc (OTCBB:ELTP) disclosed on Thursday its consolidated revenues of USD2.3m for the quarter ended 31 December 2016, the third quarter of its 2017 fiscal year.

This reflects an improvement of 6% on a year-on-year basis and the continued growth of the company's niche generic product lines drove the revenue increase.

For the Q3 of fiscal year 2017, the company spent USD1.5m for the development of its pipeline of products under its product development activities.

According to the company, its management will host a conference call to discuss the results of operations and provide an update on recent business developments on 13 February 2017 at 11:30 AM EST.